08:09 AM EDT, 04/30/2025 (MT Newswires) -- Bausch + Lomb ( BLCO ) fell 10% in U.S. pre-market trading on Wednesday after reporting a swing to a first-quarter adjusted loss.

The adjusted loss was US$54 million, or US$0.07 per share, compared with adjusted net income of US$24 million, or $0.07 per share, for the prior year period. The result missed a consensus analyst estimate of US$0.02 per share, according to Capital IQ. The profit figures exclude most one-time items, including the acquisition of Whitecap Biosciences and the voluntary recall of certain enVista products

Revenue increased 3% to US$1.137 billion.

Bausch + Lomb ( BLCO ) updated its 2025 outlook to account for the estimated impact of the enVista intraocular lens recall and foreign exchange. The company now expects revenue of US$5 billion to US$5.1 billion, up from February's forecast of US$4.95 billion to US$5.05 billion. It also expects a full-year one-time impact of US$55 million for the enVista recall on revenue.

The company's shares were last seen down US$1.43 to US$12.29 in New York trading.